In the clinical trials also reveal a potential use of panitumumab anti-EGFR combined to gemcitabine and oxaliplatin (GEMOX) chemotherapy but it did not show to improve the overall survival of CCA patient (Peraldo-Neia et al., 2018). Here, EGFR is linked to cholangiocarcinoma.